Aldo Quattrone1, Maurizio Morelli2, Andrea Quattrone3, Basilio Vescio4, Salvatore Nigro5, Gennarina Arabia2, Rita Nisticò5, Fabiana Novellino5, Maria Salsone5, Pierpaolo Arcuri6, Angelina Luca7, Alessandro Mazzuca7, Caterina Alessio8, Federico Rocca5, Manuela Caracciolo5. 1. Neuroscience Centre, Magna Graecia University, Catanzaro, Italy; Neuroimaging Research Unit, Institute of Molecular Bioimaging and Physiology, National Research Council, Catanzaro, Italy. Electronic address: quattrone@unicz.it. 2. Neuroimaging Research Unit, Institute of Molecular Bioimaging and Physiology, National Research Council, Catanzaro, Italy; Institute of Neurology, Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy. 3. Institute of Neurology, Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy. 4. Biotecnomed, S.C.aR.L, Catanzaro, Italy. 5. Neuroimaging Research Unit, Institute of Molecular Bioimaging and Physiology, National Research Council, Catanzaro, Italy. 6. Neuroimaging Research Unit, Institute of Molecular Bioimaging and Physiology, National Research Council, Catanzaro, Italy; Radiology Department, Pugliese-Ciaccio Hospital, Catanzaro, Italy. 7. Neuroimaging Research Unit, Institute of Molecular Bioimaging and Physiology, National Research Council, Catanzaro, Italy; Neuroradiology Unit, Cetraro-Paola Hospital, Cosenza, Italy. 8. Neuroimaging Research Unit, Institute of Molecular Bioimaging and Physiology, National Research Council, Catanzaro, Italy; Institute of Neuroradiology, Magna Graecia University, Catanzaro, Italy.
Abstract
INTRODUCTION: We investigated the disease progression rate in patients with progressive supranuclear palsy-Richardson syndrome (PSP-RS) and PSP-parkinsonism (PSP-P) in comparison with Parkinson disease (PD) patients, using MRPI (Magnetic Resonance Parkinsonism Index), and MRPI 2.0. METHODS: Fifteen PSP-RS patients (disease duration, y, mean ± SD: 2.5 ± 1.1), 16 PSP-P patients (disease duration, y, mean ± SD: 6.5 ± 3.2) and 19 PD patients (disease duration, y, mean ± SD: 3.2 ± 2.3) were enrolled. All patients underwent clinical assessment and MRI at baseline, 1-year, and 2-year follow-up. MRPI, MRPI 2.0 and clinical scores over 1 and 2-years were used to evaluate disease progression rate, and to calculate sample sizes required to power placebo-controlled trials. RESULTS: All groups showed increased clinical motor scores over time whereas only PSP groups had increased MRPI and MRPI 2.0 values over T1 and T2 intervals. The percentage increase over 1 and 2-years of MRPI and MRPI 2.0 values was significantly higher in PSP groups than in PD group, and in PSP-RS than in PSP-P patients while no difference between patient groups was observed when clinical motor scores were considered. Sample size estimates showed that MRPI 2.0 performed better than MRPI and clinical scales. Treatment trials with MRPI 2.0 could be performed over 2-years both in PSP-RS and PSP-P with a sample size per treatment arm of 89 and 170 patients, respectively. CONCLUSIONS: Our results demonstrate that MRPI 2.0 was more powerful than MRPI and clinical motor scales in evaluating PSP progression, and in providing the best sample size estimates for clinical trials.
INTRODUCTION: We investigated the disease progression rate in patients with progressive supranuclear palsy-Richardson syndrome (PSP-RS) and PSP-parkinsonism (PSP-P) in comparison with Parkinson disease (PD) patients, using MRPI (Magnetic Resonance Parkinsonism Index), and MRPI 2.0. METHODS: Fifteen PSP-RSpatients (disease duration, y, mean ± SD: 2.5 ± 1.1), 16 PSP-Ppatients (disease duration, y, mean ± SD: 6.5 ± 3.2) and 19 PDpatients (disease duration, y, mean ± SD: 3.2 ± 2.3) were enrolled. All patients underwent clinical assessment and MRI at baseline, 1-year, and 2-year follow-up. MRPI, MRPI 2.0 and clinical scores over 1 and 2-years were used to evaluate disease progression rate, and to calculate sample sizes required to power placebo-controlled trials. RESULTS: All groups showed increased clinical motor scores over time whereas only PSP groups had increased MRPI and MRPI 2.0 values over T1 and T2 intervals. The percentage increase over 1 and 2-years of MRPI and MRPI 2.0 values was significantly higher in PSP groups than in PD group, and in PSP-RS than in PSP-Ppatients while no difference between patient groups was observed when clinical motor scores were considered. Sample size estimates showed that MRPI 2.0 performed better than MRPI and clinical scales. Treatment trials with MRPI 2.0 could be performed over 2-years both in PSP-RS and PSP-P with a sample size per treatment arm of 89 and 170 patients, respectively. CONCLUSIONS: Our results demonstrate that MRPI 2.0 was more powerful than MRPI and clinical motor scales in evaluating PSP progression, and in providing the best sample size estimates for clinical trials.
Authors: Rosalie M Grijalva; Nha Trang Thu Pham; Qiao Huang; Peter R Martin; Farwa Ali; Heather M Clark; Joseph R Duffy; Rene L Utianski; Hugo Botha; Mary M Machulda; Stephen D Weigand; J Eric Ahlskog; Dennis W Dickson; Keith A Josephs; Jennifer L Whitwell Journal: Mov Disord Date: 2021-12-31 Impact factor: 9.698
Authors: Andrea Quattrone; Maria G Bianco; Angelo Antonini; David E Vaillancourt; Klaus Seppi; Roberto Ceravolo; Antonio P Strafella; Gioacchino Tedeschi; Alessandro Tessitore; Roberto Cilia; Maurizio Morelli; Salvatore Nigro; Basilio Vescio; Pier Paolo Arcuri; Rosa De Micco; Mario Cirillo; Luca Weis; Eleonora Fiorenzato; Roberta Biundo; Roxana G Burciu; Florian Krismer; Nikolaus R McFarland; Christoph Mueller; Elke R Gizewski; Mirco Cosottini; Eleonora Del Prete; Sonia Mazzucchi; Aldo Quattrone Journal: Mov Disord Date: 2022-04-11 Impact factor: 9.698
Authors: Andrea Quattrone; Maurizio Morelli; Maria G Bianco; Jolanda Buonocore; Alessia Sarica; Maria Eugenia Caligiuri; Federica Aracri; Camilla Calomino; Marida De Maria; Maria Grazia Vaccaro; Vera Gramigna; Antonio Augimeri; Basilio Vescio; Aldo Quattrone Journal: Brain Sci Date: 2022-07-20